• Lyudmila [she/her, comrade/them]@hexbear.netM
    link
    fedilink
    English
    arrow-up
    13
    ·
    edit-2
    9 days ago

    But like, seriously though.

    It’s insane that the FDA pulled all the coxibs for cardiovascular risk (not universally banned, but celecoxib is the only one still even available with prescription, and pretty much only for osteoarthritis) and then just left the rest of the earlier NSAIDs on the market despite them having the same cardiovascular risk!

    Straight up, 200-400 mg of celecoxib is associated with a lower risk of cardiovascular events than the equivalent dosage of ibuprofen or aspirin and avoids the stomach issues associated with traditional NSAIDs. The risk is dosage related.

    FDA doesn’t give a shit, they just wanna ban mifepristone and get rid of vaccines.

    • adultswim_antifa [he/him]@hexbear.net
      link
      fedilink
      English
      arrow-up
      6
      ·
      edit-2
      9 days ago

      That sounds a lot like how they invented ephedrine asthma inhalers and sold them over the counter, which you can give yourself a heart attack with. People died, so they decided future inhalers would have to have a prescription. Newer inhalers are safer and require a prescription, but then they left the old inhalers on the market and you can still buy them over the counter at CVS and Walgreens.

    • pr0kch0p [she/her]@hexbear.net
      link
      fedilink
      English
      arrow-up
      5
      ·
      9 days ago

      Oh, they’re trying to get rofecoxib back on the market in the US as an orphan drug for hemophilic arthropathy, despite celecoxib already existing and Vioxx having been pulled from the market after Bayer got caught hiding the obscene CV risk profile from the public. Once it’s available for people with joint damage from hemophilia there’s nothing (except a REMS program robust enough to keep it from coming back to market which, lol lmao) to stop it from being prescribed to anyone for anything.

      All of the NSAIDs have some combination of GI, CV, and nephrotoxicity risks. Celecoxib is the least worst of them, but it still exists in the shadow of Vioxx. The conventional NSAIDs (except for naproxen and aspirin) are all associated with varying degrees of GI or CV risk and nephrotoxicity. It’s a class effect, some are worse than others, celecoxib and naproxen seem to have the best risk/benefit ratio for people who can take NSAIDs.